Pharmaceuticals, Biotechnology and Life Sciences
Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat during the virtual Goldman…
Seattle Genetics gets first approval for Tukysa outside of the U.S., Switzerland’s first approval under FDA initiative project orbis.
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that, due to public health and safety concerns related to the…
Seattle Genetics has record Adcetris net sales in U.S. and Canada of $167.6 Million in the third quarter, an increase…
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.
Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 7,142,858 shares of…
-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology- BOTHELL,…
Seattle Genetics has announced the appointment ofRobin G. Taylor, M.B.A., Ph.D., as Chief Commercial Officer